A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer

A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer

Abstract More than half of non‐muscle‐invasive bladder cancer (NMIBC) patients eventually relapse even if treated with surgery and BCG without optional bladder‐preserving therapy. This study aims to investigate the antitumor activity and safety of a HER2‐targeted antibody‐drug conjugate, RC48‐ADC, i...

Full description

Bibliographic Details
Main Authors: Xuwei Hong, Xu Chen, Hongjin Wang, Qingchun Xu, Kanghua Xiao, Yuanfeng Zhang, Zepai Chi, Yeqing Liu, Guangyao Liu, Hong Li, Jianmin Fang, Tianxin Lin, Yonghai Zhang
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:Advanced Science
Subjects:
antitumor activity
HER2
intravesical instillation
non‐muscle‐invasive bladder cancer
RC48‐ADC
Online Access:https://doi.org/10.1002/advs.202302377

Internet

https://doi.org/10.1002/advs.202302377

Similar Items